Descriptive data of lysophosphatidylcholine (lysoPC) measured in units received by control patients and TRALI patients
| . | Units received by control patients (N = 536) . | Units received by TRALI patients (N = 419) . |
|---|---|---|
| LysoPC concentration, M, mean ± SD | 128 ± 78.3 | 142 ± 80.6 |
| LysoPC concentration, M, median (range) | 137 (0.2-453) | 152 (1-367) |
| . | Units received by control patients (N = 536) . | Units received by TRALI patients (N = 419) . |
|---|---|---|
| LysoPC concentration, M, mean ± SD | 128 ± 78.3 | 142 ± 80.6 |
| LysoPC concentration, M, median (range) | 137 (0.2-453) | 152 (1-367) |
LysoPC concentration was the sum of the concentrations of the 16:0 and 18:0 fatty acid moieties. In risk factor analysis, the sum of lysoPC quantities among all units received by a patient was a statistically significant risk factor in univariate analysis (Table 9) but not in multivariate analysis.